Gallium-68 Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Gallium-68 Market Trends and Insights

PSMA PET Adoption Accelerated by Approvals and Guideline Endorsements

Multiple 2025 regulatory milestones converted PSMA PET from optional to standard practice in staging and recurrence assessment. Telix’s Gozellix gained FDA clearance in March 2025 with a six-hour shelf life that lets radiopharmacies batch morning syntheses for afternoon scans, trimming labor costs 15-20%. NCCN Prostate Cancer Guidelines v1.2025 elevated PSMA PET to Category 1 evidence for high-risk disease, expanding eligible U.S. patients by roughly 40%^{[1]NCCN, “NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer, Version 1.2025,” NCCN.ORG}. Japan’s simultaneous approval of Locametz, GalliaPharm, and Pluvicto created a reimbursed theranostic pathway priced at JPY 550,000 (USD 3,700) per scan. China accepted the Illuccix NDA in January 2026 on the strength of a 94.8% positive-predictive study in more than 134,000 annual cases, setting the stage for a late-2026 launch. U.S. procedure volumes topped 350,000 in 2024, a 30% jump that underscores payer adoption.

Sustained Demand from SSTR Imaging in NETs

Ga-68 DOTATATE and DOTATOC maintain a stable revenue base because neuroendocrine tumor (NET) incidence continues to rise in aging populations and because Lu-177 DOTATATE therapy requires serial diagnostic scans before and during treatment. A 2025 Chinese comparative study confirmed that Ga-68 DOTATATE outperforms F-18 FDG for well-differentiated NET detection, reinforcing physician preference for somatostatin-receptor tracers^{[2]Jianwei Li, “Ga-68 DOTATATE Outperforms F-18 FDG in Well-Differentiated NETs,” Frontiers in Oncology, frontiersin.org}. Longitudinal operating data from the University of Parma show roughly 610 DOTATOC batches through 2024, proving that SSTR use remains robust even as PSMA volumes surge. The isotope’s 68-minute half-life aligns with somatostatin analog pharmacokinetics, yielding high lesion-to-background ratios within an hour of injection. That clinical efficiency anchors shipments when PSMA supply is disrupted, cushioning overall market revenue during competitive cycles.

Greater Availability of Higher-Activity Generators Expands Access

Eckert & Ziegler’s 100 mCi GalliaPharm generator, cleared in the European Economic Area in August 2024 and in Japan in September 2025, more than triples daily elutions compared with legacy 50 mCi units and cuts the ready-to-use interval to under one hour. Validation at the University of Michigan confirmed that Locametz kits tolerate up to 3.16 GBq per synthesis, enabling four to five patient doses per run and reducing reagent cost 20-25%. Sichuan University’s TiO₂ column produced 3.26 GBq with 79.8% efficiency, indicating that academic labs are pushing generator ceilings and decreasing reliance on imported cores. Higher activity extends reach: a single 100 mCi generator can serve several satellite hospitals via courier, lowering capital outlays for facilities that lack a cyclotron. These improvements maintain generator relevance even as cyclotron supply ramps.

Cyclotron-Produced Ga-68 Scaling Augments Supply Capacity

ARTMS Quantitative Isotope Separation (QIS) technology yields up to 5,000 mCi from a two-hour liquid Zn-68 irradiation, roughly 60-times a single generator elution, letting radiopharmacies batch 40-50 patient doses overnight. Cardinal Health has integrated QIS at more than 110 licensed sites, enabling next-day delivery within 200 miles and removing the need for hospitals to manage generators or hot-lab staff. University of Michigan analytics show cyclotron-produced Ga-68 meets FDA and European Pharmacopoeia specifications across PSMA-11, DOTATOC, and FAPI kits, dispelling earlier purity concerns. Jubilant Radiopharma is adding five IBA Cyclone KIUBE 180 units, signaling that mid-tier chains see value in dual-isotope lines that co-produce FDG and Ga-68 at scale. This bulk activity buffers the Gallium-68 supply chain against Ge-68 shortages and supports national distribution strategies that mirror FDG logistics.

Competition from F-18 PSMA Agents with Wider Distribution

Lantheus’ Pylarify TruVu, approved in March 2026, exploits F-18’s 110-minute half-life to supply imaging centers up to 500 miles away, creating a structural cost and reach advantage over Ga-68 kits. U.S. uptake exceeded 760,000 scans by 2024, and larger 20-dose syntheses lower per-patient costs roughly 25-30%. Installed F-18 cyclotrons already outnumber Ga-68 generators four-to-one, letting hospitals add PSMA labeling with little incremental capital^{[3]FDA, “Drug Approval Package: Locametz,” FDA.GOV}. Switzerland’s 2025 approval of Pylclari signals a pending wave of European entrants. As more F-18 competitors secure reimbursement, Ga-68 conversion in rural areas may plateau near 60-70% of the PSMA opportunity.

Short Half-Life and Generator Logistics/Quality-Control Constraints

Ga-68’s 68-minute half-life compresses the window for elution, labeling, QC testing, and injection to about six hours, capping feasible courier radii at roughly 200 miles, whereas F-18’s 110-minute half-life supports 500-mile routes. Quality-control steps, pH, radionuclidic purity, Ge-68 breakthrough, and sterility, consume 30-45 minutes, shortening the imaging window if patient flow is delayed. Generator activity decays daily; a 100 mCi unit yields near 80 mCi on day 1 but only 40 mCi by day 7, forcing tight scheduling to avoid isotope wastage. Rural sites without a local radiopharmacy cannot rely on same-day delivery, leaving them dependent on F-18 agents or foregoing advanced imaging.

Segment Analysis

By Production Route: Cyclotron Gains Share Despite Generator Dominance

Generator-based supply retained 82.18% of the Gallium-68 market in 2025, but cyclotron activity is rising at an 18.76% CAGR as networks deploy ARTMS QIS and IBA Cyclone platforms capable of over 5,000 mCi per two-hour run. That scale supports 40-50 patient doses, driving down per-dose costs and expanding the practical service radius to 200 miles. Generator lines still suit academic centers managing 2-4 daily scans; the recently approved 100 mCi GalliaPharm unit lifts daily elutions from three to ten, preserving relevance where on-site throughput matters. Sichuan University’s 3.26 GBq TiO₂ generator prototype shows that academic R&D continues to push generator ceilings.

The cyclotron build-out also diversifies supply risk that once hinged on three German-designed generator brands, a vulnerability exposed by Eckert & Ziegler’s 2025 cyberattack. Radiopharmacies view dual-isotope production as a hedge: a single facility can mint both FDG and Ga-68 doses, amortizing capital faster than single-nuclide sites. Hospitals, meanwhile, gain flexibility, generators for low-volume days, cyclotron deliveries for peak PSMA clinics, without breaching radiation licensing caps. Overall, increasing route optionality underpins resilience in the Gallium-68 market.

By Product: Ready-to-Use Doses Gain as Radiopharmacies Absorb Labeling

PSMA-11 cold kits accounted for 44.38% of 2025 revenue, but the shipment of radiopharmacy-prepared doses is escalating 19.15% annually as facilities outsource labeling to specialized compounders. Telix’s purchase of RLS added 31 pharmacies and vertically integrated everything from eluate to courier van, capturing both kit and service margin. Six-hour shelf-life Gozellix further supports morning synthesis for afternoon deliveries, smoothing courier logistics across multi-state regions. In contrast, hospitals that keep generators in-house shoulder USP 825/797 sterility workflows, daily Ge-68 breakthrough checks, and media-fill validations, burdens that radiopharmacies spread across high volume.

SSTR cold kits for neuroendocrine tumors remain a resilient niche; NETSPOT and DOTATOC enjoy stable reimbursement and continue to anchor demand where PSMA volumes have yet to dominate. The near-term pipeline suggests a similar adoption curve for FAPI kits: academic hospitals will label in-house through Phase III trials, then migrate to outsourced doses once payers codify procedure codes. This gradual pivot toward service-based delivery reinforces the service revenue stream inside the Gallium-68 market.

By Radiopharmaceutical / Indication: PSMA Leads, FAPI Surges

Prostate-cancer imaging commanded 61.39% of the Gallium-68 market share in 2025 on the back of more than 350,000 U.S. scans and NCCN Category 1 endorsement for high-risk staging and low-PSA recurrence. Japan’s reimbursement listing at JPY 550,000 (USD 3,700) per procedure and China’s NDA acceptance promise to lift regional volumes in 2026–2027. Neuroendocrine-tumor imaging remains a dependable second line; Ga-68 DOTATATE outperformed FDG for well-differentiated lesions in a 2025 Chinese study, preserving physician loyalty.

FAPI imaging is on a 19.66% CAGR trajectory as Phase I/II data across 500-plus patients show positive-predictive values above 90% in pancreatic, breast and sarcoma cohorts. SOFIE’s licensing of FAPI-46 and FAPI-74 and Philogen’s OncoFAP results (SUVmax ≈ 9.4) position first movers for 2027 submissions. Pan-cancer flexibility lets radiopharmacies run PSMA, SSTR and FAPI from one generator cycle, improving labor utilization and diluting inventory risk.

By End User: Radiopharmacies Capture Outsourcing Wave

Hospitals and academic centers generated 58.59% of 2025 demand, reflecting legacy generator ownership and established hot-lab teams. Yet centralized radiopharmacies recorded 19.34% annual growth after Telix bought RLS’s 31 sites and Siemens Healthineers folded 60 PETNET locations into its modality business, creating a combined footprint exceeding 190 facilities with Ga-68 licenses. These hubs amortize USP 825/797 sterility protocols and FDA 21 CFR 212 compliance across hundreds of daily doses, bringing per-scan costs down 15-20% for community hospitals that cannot justify ISO Class 5 clean-rooms.

As bulk cyclotron supply and six-hour shelf-life kits broaden 200-mile courier zones, smaller imaging centers increasingly opt for delivered doses rather than managing Ge-68 breakthrough testing on site. The Gallium-68 market is expected to grow in North America and Australia where network density already supports same-day fulfillment. Europe and parts of Asia will shift more gradually because reimbursement still favors on-site preparation, but tightening EMA Annex 3 GMP rules should accelerate outsourcing mid-forecast.

Geography Analysis

North America generated 48.19% of 2025 revenue as hospitals executed more than 350,000 PSMA PET scans and as the NCCN upgrade boosted guideline-driven demand. Telix strengthened vertical control by acquiring RLS Radiopharmacy Solutions, adding 31 sites that synchronize generator elution, cyclotron output, and last-mile couriers. Cardinal Health operates more than 130 nuclear pharmacies, 110 of which hold Ga-68 licenses, underpinning same-day delivery across most U.S. metropolitan clusters. Canada added Locametz in 2023, while Mexico’s PET/CT fleet exceeded 50 cameras by 2025, although limited radiopharmacy density tempers penetration outside primary cities. Lantheus’ Pylarify TruVu approval now provides an F-18 alternative that may capture rural demand where Gallium-68 logistics remain challenging. 

Asia-Pacific advances at a 21.65% CAGR as Japan approved Locametz, Pluvicto, and 100 mCi generators in September 2025 and set reimbursement at JPY 550,000 (USD 3,700) per scan across 108 hospitals. China’s NMPA accepted the Illuccix NDA in January 2026, backed by a pivotal trial showing 94.8% positive predictive value in over 134,000 annual prostate-cancer cases, and the country’s PET/CT install base passed 1,600 cameras in 2025, positioning it for rapid uptake.

Europe retains a generator-centric model anchored by university hospitals; Eckert & Ziegler’s 100 mCi GalliaPharm approval doubled daily elutions and mitigated backlog risk after its 2025 cyberattack disrupted shipments for several weeks. Although GCC states and Brazil invest in PET infrastructure, limited radiopharmacy networks restrict Gallium-68 to urban hubs; in these regions, F-18’s longer half-life currently offers broader coverage.